

Liquid rFGF-2 Formulations

CN-RP-HPLC

% Main Peak

4°C




Figure 1

rFGF-2 Liquid Formulations

CN-RP-HPLC

% Main Peak

17°C




Figure 2

rFGF-2 Liquid Formulations

CN-RP-HPLC

% Main Peak

30°C




Figure 3

Liquid rFGF-2 Formulations % Main Peak CN-RP-HPLC 30°C




Figure 4

Title: Stabilized FGF Formulations Containing Reducing Agents
Inventor(s): Robert V. Hageman, Bret A. Shirley, Kamaljit K. Bajwa
Application No.: Pp16021.002 (35784/213736)
Attorney

Lyophilized rFGF-2 Formulations

CN-RP-HPLC

% Main Peak

40°C




Figure 5

All formulations contain:

10 mM sodium citrate
2% glycine
1% sucrose
1 mM EDTA

Title: Stabilized FGF Formulations Containing Reducing Agents
Inventor(s): Robert V. Hageman, Bret A. Shirley, Kamaljit K. Bajwa
Application No: Not yet assigned
Atty Dkt No: PP16021.002 (35784/213736)


Lyophilized rFGF-2 Formulations

CN-RP-HPLC

% Main Peak

50°C

Title: Stabilized FGF Formulations Containing Reducing Agents
 Inventor(s): Robert V. Hageman, Bret A. Shirley, Kamaljit K. Bajwa
 Application No: Not yet assigned
 Atty Dkt No: PP16021.002 (35784/213736)



- 0% Acetyl Cysteine / 0 mM DTT pH 5.5
- 0.5% Acetyl Cysteine pH 5.5
- ▲ 10 mM DTT pH 5.5
- ▼ 0.5% Acetyl Cysteine / 10 mM DTT pH 5.5
- ◆ 0.5% Acetyl Cysteine pH 6.0
- 10 mM DTT pH 6.0
- 0.5% Acetyl Cysteine / 10 mM DTT pH 6.0
- △ 0.5% Acetyl Cysteine pH 6.5
- ▽ 10 mM DTT pH 6.5
- ◇ 0.5% Acetyl Cysteine / 10 mM DTT pH 6.5

Weeks

Figure 6

All formulations contain:

10 mM sodium citrate
 2% glycine
 1% sucrose
 1 mM EDTA

rhFGF2 Stability
30°C
RP-HPLC
% Main Peak




Figure 7